Provided by Tiger Trade Technology Pte. Ltd.

Larimar Therapeutics, Inc.

2.96
-0.1000-3.27%
Post-market: 2.960.00000.00%19:30 EDT
Volume:834.96K
Turnover:2.48M
Market Cap:307.84M
PE:-1.54
High:3.11
Open:3.11
Low:2.92
Close:3.06
52wk High:6.42
52wk Low:2.72
Shares:104.00M
Float Shares:57.54M
Volume Ratio:0.51
T/O Rate:1.45%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.9258
EPS(LYR):-2.2711
ROE:-139.63%
ROA:-70.96%
PB:2.42
PE(LYR):-1.30

Loading ...

Top Premarket Decliners

MT Newswires Live
·
Jun 29

Larimar Therapeutics submits first module of rolling BLA for nomlabofusp

TIPRANKS
·
Jun 29

Larimar Therapeutics Submits First Module of Rolling BLA to FDA for Nomlabofusp in Friedreich’s Ataxia

Reuters
·
Jun 29

Larimar Therapeutics - First Patient Dosing in Phase 3 Study Expected Q3 2026

THOMSON REUTERS
·
Jun 29

Larimar Therapeutics - Nomlabofusp Long-term Dosing Generally Well-tolerated; Anaphylaxis in 10 of 43 Patients

THOMSON REUTERS
·
Jun 29

Larimar Therapeutics - Submits First Module of Rolling Bla for Nomlabofusp; Remaining Modules Expected 2H 2026

THOMSON REUTERS
·
Jun 29

Larimar Therapeutics to Host Investor Webcast on Nomlabofusp Program for Friedreich’s Ataxia

Reuters
·
Jun 27

U.S. RESEARCH ROUNDUP- Agilent Technologies, Fedex, Synopsys

Reuters
·
May 27

Larimar Therapeutics Inc : JP Morgan Initiates Coverage With Overweight Rating; Price Target $9

THOMSON REUTERS
·
May 27

Larimar Therapeutics shareholders approve increase in authorized common shares to 215 million

Reuters
·
May 20

Exploring US High Growth Tech Stocks This May 2026

Simply Wall St.
·
May 15

Larimar Therapeutics Q1 net loss widens slightly R&D expenses fall

Reuters
·
May 14

BRIEF-Larimar Therapeutics Q1 Net Income USD -29.613 Million

Reuters
·
May 14

Larimar Therapeutics Q1 EPS USD -0.31

THOMSON REUTERS
·
May 14

Larimar Therapeutics Reports First Quarter 2026 Financial and Business Update

THOMSON REUTERS
·
May 14

Top News Today: Stocks Rise, Oil Falls, as War Restart Fears Subside

Dow Jones
·
May 06

Larimar study backs skin frataxin as surrogate endpoint for nomlabofusp trials

Reuters
·
May 01

Larimar Therapeutics Inc expected to post a loss of 54 cents a share - Earnings Preview

Reuters
·
Apr 24

Larimar Therapeutics announces annual stockholder meeting

Reuters
·
Apr 11